KW 2189

structure given in first source

Also Known As:

Benzo(1,2-b:4,3-b')dipyrrole-1-carboxylic acid, 8-(bromomethyl)-3,6,7,8-tetrahydro-2-methyl-4-(((4-methyl-1-piperazinyl)carbonyl)oxy)-6-((5,6,7-trimethoxy-1H-indol-2-yl)carbonyl)-, methyl ester, (S)-; KW-2189; methyl(1S)-1-bromomethyl-7-methyl-5-((4-methylpiperazinyl)carbonyloxy)-3-((5,6,7-trimethoxy-2-indolyl)carbonyl)-1,2-dihydro-3H-pyrrolo(3,2-e)indole-8-carboxylate hydrobromide

Networked: 10 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - Duocarmycins: 63
        KW 2189: 10
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Duocarmycins: 63
        KW 2189: 10

Experts

1.	Alberts, Steven R: 2 articles (01/2007 - 06/2002)
2.	Suman, Vera J: 2 articles (01/2007 - 06/2002)
3.	Camoriano, John K: 1 article (01/2007)
4.	Pitot, Henry C: 1 article (01/2007)
5.	Rubin, Joseph: 1 article (01/2007)
6.	Adjei, Alex A: 1 article (06/2002)
7.	Braich, Theodore A: 1 article (06/2002)
8.	Creagan, Edward T: 1 article (06/2002)
9.	Fitch, Tom R: 1 article (06/2002)
10.	Hillman, David W: 1 article (06/2002)

Related Diseases

1.	Neoplasms (Cancer) 05/01/1994 - "The most remarkable feature of KW-2189 was its efficacy against various human xenografts, which was observed in 14 tumors among 16 tested tumors including drug-insensitive tumors by single i.v. administration. " 01/01/2007 - "KW-2189 showed evidence of anti-tumor activity in HCC. " 09/01/1998 - "We conducted a Phase I trial of KW-2189 in patients who had solid tumors that were refractory to standard chemotherapy or for whom no more effective therapy existed. " 06/01/2002 - "KW-2189, a semisynthetic duocarmycine antibiotic has been shown to exert antiproliferative effects against human tumor cell lines in vitro and animal tumor models in vivo. " 09/01/1998 - "KW-2189 is a water-soluble semisynthetic derivative of duocarmycin B2, with significant activity in murine and human tumor models. "
2.	Leukemia P388 05/01/1994 - "KW-2189 was also effective against murine P388 leukemia and L1210 leukemia not only by local administration (i.p.-i.p. "
3.	Leukemia L1210 05/01/1994 - "KW-2189 was also effective against murine P388 leukemia and L1210 leukemia not only by local administration (i.p.-i.p. "
4.	Melanoma (Melanoma, Malignant) 06/01/2002 - "Presented are two concurrent phase II studies assessing the antitumor and toxicity profile of KW-2189 in metastatic melanoma patients. " 06/01/2002 - "In summary, the lack of significant antitumor activity of KW-2189 and its associated toxicity suggest that further testing of this regimen in patients with stage IV melanoma is not warranted."
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/01/1994 - "Cytotoxic activity was examined by exposing a human small cell lung cancer cell line, NCI-H69 to KW-2189 with or without carboxyl esterase. " 04/01/1994 - "A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells." 01/01/1995 - "Three duocarmycins, KW-2189, DU-86 and duocarmycin SA, were active against the cisplatin (CDDP)-resistant human non-small cell lung cancer cell lines PC-9/CDDP and PC-14/CDDP, and the multidrug-resistant human small cell lung cancer cell line H69/VP. "

Related Drugs and Biologics

1.	Duocarmycins
2.	Cisplatin (Platino)
3.	Anti-Bacterial Agents (Antibiotics)
4.	DU 86
5.	duocarmycin B2
6.	A-Form DNA (A-DNA)
7.	Prodrugs
8.	Esterases
9.	DNA (Deoxyribonucleic Acid)
10.	Caffeine (No Doz)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)